title: Ultrasound contrast agent delivered per os first diagnoses pharyngoesophageal tumour.
abstract: Oral administration of ultrasound contrast agents has been described very little so far in medical literature. These agents are mainly administered intravenously and, less commonly, intracavitarily. We present the case of a patient with a cervical mass in whom sonographic examination with per os administration of SonoVue led to the diagnosis of a pharyngoesophageal tumour. The diagnosis was confirmed on barium swallow and endoscopy-guided biopsy.
authors.affiliation: Radiology Department, Evangelismos Hospital, Athens, Greece.
authors.forename: E
authors.initials: E
authors.lastname: Antypa
authors.forename: D D
authors.initials: DD
authors.lastname: Cokkinos
authors.forename: I
authors.initials: I
authors.lastname: Kalogeropoulos
authors.forename: D
authors.initials: D
authors.lastname: Tomais
authors.forename: P N
authors.initials: PN
authors.lastname: Piperopoulos
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001706:Biopsy; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging*; D003287:Contrast Media / Q000008:administration & dosage*; D003937:Diagnosis, Differential; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging*; D004945:Esophagoscopy; D006801:Humans; D008297:Male; D010610:Pharyngeal Neoplasms / Q000000981:diagnostic imaging*; D010743:Phospholipids / Q000008:administration & dosage*; D013459:Sulfur Hexafluoride / Q000008:administration & dosage*; D014463:Ultrasonography
chemical_list: D003287:Contrast Media; D010743:Phospholipids; C420843:contrast agent BR1; D013459:Sulfur Hexafluoride